Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
5.24 (1y: +49%)
Market Cap 377.16 M P/E(ttm)
Enterprise Value 314.96 M P/B 16.70
CERS- NAS (USA)
Cerus Corporation
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$5.24
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry		 vs
history
Cash to Debt 3.456
CERS's Cash to Debt is ranked lower than
66% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CERS: 3.456 )
CERS' s 10-Year Cash to Debt Range
Min: 1.97   Max: No Debt
Current: 3.46
Equity to Asset 0.332
CERS's Equity to Asset is ranked lower than
69% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. CERS: 0.332 )
CERS' s 10-Year Equity to Asset Range
Min: 0.21   Max: 0.87
Current: 0.33
0.21
0.87
F-Score: 3
Z-Score: 0.54
M-Score: -2.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry		 vs
history
Operating margin (%) -47.00
CERS's Operating margin (%) is ranked higher than
54% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. CERS: -47.00 )
CERS' s 10-Year Operating margin (%) Range
Min: -2168.2   Max: -26.6
Current: -47
-2168.2
-26.6
Net-margin (%) -43.3
CERS's Net-margin (%) is ranked higher than
56% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. CERS: -43.3 )
CERS' s 10-Year Net-margin (%) Range
Min: -1946.7   Max: 53.6
Current: -43.3
-1946.7
53.6
ROE (%) -83.3
CERS's ROE (%) is ranked lower than
62% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. CERS: -83.3 )
CERS' s 10-Year ROE (%) Range
Min: -145   Max: 37
Current: -83.3
-145
37
ROA (%) -32.5
CERS's ROA (%) is ranked lower than
55% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. CERS: -32.5 )
CERS' s 10-Year ROA (%) Range
Min: -78.4   Max: 22.3
Current: -32.5
-78.4
22.3
Revenue Growth (%) 6.5
CERS's Revenue Growth (%) is ranked higher than
80% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. CERS: 6.5 )
CERS' s 10-Year Revenue Growth (%) Range
Min: -20.8   Max: 37.5
Current: 6.5
-20.8
37.5
EBITDA Growth (%) -17.9
CERS's EBITDA Growth (%) is ranked higher than
65% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. CERS: -17.9 )
CERS' s 10-Year EBITDA Growth (%) Range
Min: -43.7   Max: 26.4
Current: -17.9
-43.7
26.4
EPS Growth (%) -16.8
CERS's EPS Growth (%) is ranked higher than
64% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. CERS: -16.8 )
CERS' s 10-Year EPS Growth (%) Range
Min: -50.5   Max: 39.9
Current: -16.8
-50.5
39.9
ยป CERS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

CERS Guru Trades in Q2 2012

Chuck Royce 4,523,011 sh (unchged)
Jim Simons Sold Out
» More
Q3 2012

CERS Guru Trades in Q3 2012

Chuck Royce 4,523,011 sh (unchged)
» More
Q4 2012

CERS Guru Trades in Q4 2012

Chuck Royce 4,523,011 sh (unchged)
» More
Q1 2013

CERS Guru Trades in Q1 2013

Jim Simons 172,023 sh (New)
Chuck Royce 4,523,011 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CERS



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 16.70
CERS's P/B is ranked lower than
74% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CERS: 16.70 )
CERS' s 10-Year P/B Range
Min: 0.59   Max: 21.08
Current: 16.7
0.59
21.08
P/S 7.90
CERS's P/S is ranked higher than
63% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. CERS: 7.90 )
CERS' s 10-Year P/S Range
Min: 1.24   Max: 537.5
Current: 7.9
1.24
537.5
EV-to-EBIT 1.9
CERS's EV-to-EBIT is ranked higher than
93% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. CERS: 1.9 )
CERS' s 10-Year EV-to-EBIT Range
Min: 33.1   Max: 61
Current: 1.9
33.1
61

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 37.4
CERS's Price/Net Current Asset Value is ranked higher than
68% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. CERS: 37.4 )
CERS' s 10-Year Price/Net Current Asset Value Range
Min: 2   Max: 160.1
Current: 37.4
2
160.1
Price/Tangible Book 19.4
CERS's Price/Tangible Book is ranked higher than
89% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. CERS: 19.4 )
CERS' s 10-Year Price/Tangible Book Range
Min: 0.7   Max: 12
Current: 19.4
0.7
12
Price/Median PS Value 1.2
CERS's Price/Median PS Value is ranked higher than
70% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. CERS: 1.2 )
CERS' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 81.8
Current: 1.2
0.2
81.8
Earnings Yield (Greenblatt) 53.90
CERS's Earnings Yield (Greenblatt) is ranked higher than
93% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. CERS: 53.90 )
CERS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 64.5
Current: 53.9
1.6
64.5
Forward Rate of Return (Yacktman) -35.38
CERS's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. CERS: -35.38 )
CERS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -83.5   Max: -72.5
Current: -35.38
-83.5
-72.5

Business Description

Cerus Corporation was incorporated in California in September 1991. It is a biomedical products Company which focuses on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company has worldwide rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received CE marks and are being marketed and sold in a number of countries in Europe, The Commonwealth of Independent States, or CIS, the Middle East and selected countries in other regions around the world. The Company sells both the platelet and plasma systems using its direct sales force and through distributors. In addition, the Company is developing and plan to perform the required clinical trials for its INTERCEPT Blood System for red blood cells, or red blood cell system, for approval in Europe. The Company and its products are comprehensively regulated in the United States by the FDA and, in some instances, by state and local governments, and by comparable governmental authorities in other countries.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:CU2.Germany
ยป More Articles for CERS

Headlines

Articles On GuruFocus.com
Cerus Corp. Reports Operating Results (10-K) Mar 16 2011 
Cerus Corp. Reports Operating Results (10-Q) Aug 16 2010 
Cerus Corp. Reports Operating Results (10-Q) May 12 2010 
Cerus Corp. Reports Operating Results (10-Q) Nov 06 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial